Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis.

Author(s): Uhlenhake EE, Feldman SR

Affiliation(s): Wayne State University School of Medicine, Department of Dermatology, 18100 Oakwood Boulevard, Suite 300, Dearborn, Michigan 48124, USA. euhlenha@neoucom.edu

Publication date & source: 2010-07, Expert Opin Biol Ther., 10(7):1105-12.

Publication type: Review

IMPORTANCE OF THE FIELD: TNF-alpha inhibitors such as etanercept have been used for psoriasis for years. A fairly well defined efficacy and safety profile has developed. A new biologic agent, ustekinumab, an IL-12 and IL-23 inhibitor, has recently been released in the US for the treatment of moderate-to-severe psoriasis. The purpose of this article is to compare the efficacy and safety profiles of ustekinumab and etanercept. AREAS COVERED IN THIS REVIEW: We examined safety and efficacy data regarding ustekinumab and etanercept from clinical reports, a head-to-head trial, review articles, and databases and registries from the last 20 years. WHAT THE READER WILL GAIN: Evidence is reviewed about the efficacy for the treatment of psoriasis as well as the safety profiles for both agents, ustekinumab and etanercept. TAKE HOME MESSAGE: Both drugs have data to confirm efficacy and safety in patients with moderate-to-severe psoriasis in the short-term. The limited long-term data on the safety profile of ustekinumab requires careful judgment on the clinician's part, weighing well-defined benefits and potential unknown risks.